A major investigation is underway at Shanghai Jiao Tong University following reports that a six-year-old girl died after receiving an experimental gene-editing treatment. The child, referred to by the pseudonym Mei, passed away in March 2025, just one week after undergoing a procedure designed to address a rare genetic condition that caused mild cognitive impairment. The treatment, which involved a spinal infusion of viruses to edit genes in the brain, was led by neuroscientist Zilong Qiu at the university's affiliated Xinhua Hospital.
The case has drawn significant attention because the child's death was not publicly disclosed by the research team. According to reports, the girl's parents contributed over $800,000 to fund the research, yet they were allegedly not fully informed of the potential risks involved in the procedure. An internal hospital ethics board report reportedly concluded that the child's death was directly linked to the infusion treatment. Despite this, the research team later published findings in a prestigious journal regarding related animal studies without mentioning the fatal outcome of the human trial.
This incident has sparked a broader conversation about the oversight of clinical trials in China's rapidly growing biotechnology sector. While the country has made significant strides in medical innovation, this case highlights concerns regarding transparency, informed consent, and the ethical standards applied to early-stage human experiments. Shanghai Jiao Tong University has established a special working group to conduct a comprehensive investigation and has pledged to take serious action based on their findings.
As the investigation proceeds, the medical community is closely watching how Chinese regulators will respond to these allegations. The case serves as a stark reminder of the human risks associated with pioneering medical technologies, particularly when those technologies are applied to non-life-threatening conditions. The future of similar gene-editing research in China may now depend on the outcome of this probe and the potential implementation of stricter safety and reporting requirements.